Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Inks Deal with Insurer Three Rivers for NGS Cancer Test

NEW YORK (GenomeWeb) – Molecular diagnostics firm Paradigm announced today that it has signed a deal under which its PCDx next-generation sequencing-based cancer test will be covered by health insurer Three Rivers Provider Network.

According to Paradigm, Three Rivers has more than 15 million US members.

"We continue to make strong progress with provider networks to ensure our best-in-class NGS test is available to the millions of Americans who are suffering with cancer," Paradigm CEO Robert Penny said in a statement. "With this contract, millions of patients and their treating clinicians will have access to our leading oncology testing service and make possible more informed and individually tailored treatment strategies."

Paradigm recently announced that it entered into a contract with preferred provider organization Stratose to cover the PCDx test.